Glioblastoma stem-like cells: At the root of tumor recurrence and a therapeutic target

Carcinogenesis

Volumn 36, Issue 2, 2014, Pages 177-185

  Jackson, Melanie ^a   Hassiotou, Foteini ^a   Nowak, Anna ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE MARKER; TRANSCRIPTION FACTOR; TYROSINE KINASE RECEPTOR; CD133 ANTIGEN; CD44 PROTEIN, HUMAN; GLYCOPROTEIN; HERMES ANTIGEN; LEUKOCYTE ANTIGEN; PEPTIDE; PROTEIN TYROSINE KINASE;

CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; GLIOBLASTOMA; GLIOMA; GLIOMA STEM CELL; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR SEEDING; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR RECURRENCE;

ANTIGENS, CD; ANTIGENS, CD44; BRAIN NEOPLASMS; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; PEPTIDES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84928194762     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu243     Document Type: Review

References (108)

1. Damodaran, O. et al. (2014) Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy. J. Clin. Neurosci., 21, 478-481.
2. Colman, H. et al. (2010) A multigene predictor of outcome in glioblastoma. Neuro Oncol., 12, 49-57.
3. Verhaak, R.G. et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17, 98-110.
4. Brennan, C.W. et al. (2013) The somatic genomic landscape of glioblastoma. Cell, 155, 462-477.
5. Chen, J. et al. (2012) Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell, 149, 36-47.
6. Jun, H.J. et al. (2014) Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma. Stem Cells, 32, 338-348.
7. Singh, S.K. et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res., 63, 5821-5828.
8. Clarke, M.F. et al. (2006) Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res., 66, 9339-9344.
9. Stupp, R. et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 352, 987-996.
10. Hegi, M.E. et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med., 352, 997-1003.
11. Thomas, L. et al. (2013) Predictive biomarkers in adult gliomas: the present and the future. Curr. Opin. Oncol., 25, 689-694.
12. Phillips, H.S. et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 9, 157-173.
13. Cancer Genome Atlas Research Network. (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061-1068.
14. Beier, D. et al. (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res., 67, 4010-4015.
15. Shah, N. et al. (2013) Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data. BMC Genomics, 14, 818.
16. Nowell, P.C. (1976) The clonal evolution of tumor cell populations. Science, 194, 23-28.
17. Frank, N.Y. et al. (2010) The therapeutic promise of the cancer stem cell concept. J. Clin. Invest., 120, 41-50.
18. Gupta, P.B. et al. (2009) Cancer stem cells: mirage or reality? Nat. Med., 15, 1010-1012.
19. Kumar, S.M. et al. (2012) Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene, 31, 4898-4911.
20. Chen, J. et al. (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature, 488, 522-526.
21. Dieter, S.M. et al. (2011) Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell, 9, 357-365.
22. Economopoulou, P. et al. (2012) The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. Oncologist, 17, 1394-1401.
23. Fillmore, C.M. et al. (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res., 10, R25.
24. Li, L. et al. (2010) Coexistence of quiescent and active adult stem cells in mammals. Science, 327, 542-545.
25. Hanahan, D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
26. Abbott, A. (2006) Cancer: the root of the problem. Nature, 442, 742-743.
27. Meacham, C.E. et al. (2013) Tumour heterogeneity and cancer cell plasticity. Nature, 501, 328-337.
28. Takebe, N. et al. (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol., 8, 97-106.
29. Tanaka, H. et al. (2009) The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells. Anticancer Res., 29, 2147-2157.
30. Yan, C. et al. (2013) Drugging the undruggable: transcription therapy for cancer. Biochim. Biophys. Acta, 1835, 76-85.
31. Singh, S.K. et al. (2004) Identification of human brain tumour initiating cells. Nature, 432, 396-401.
32. Galli, R. et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res., 64, 7011-7021.
33. Friedmann-Morvinski, D. et al. (2012) Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science, 338, 1080-1084.
34. Sanai, N. et al. (2004) Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature, 427, 740-744.
35. Doetsch, F. et al. (1999) Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell, 97, 703-716.
36. Ricci-Vitiani, L. et al. (2008) Mesenchymal differentiation of glioblastoma stem cells. Cell Death Differ., 15, 1491-1498.
37. Tlsty, T.D. et al. (2001) Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev., 11, 54-59.
38. Scadden, D.T. (2006) The stem-cell niche as an entity of action. Nature, 441, 1075-1079.
39. Fuchs, E. et al. (2004) Socializing with the neighbors: stem cells and their niche. Cell, 116, 769-778.
40. Wang, L., et al. (2013) The impact of tumor microenvironments on stem cells. Transl. Cancer Res., 2, 422-428.
41. Lim, D.A. et al. (2007) Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol., 9, 424-429.
42. Liu, C. et al. (2011) Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell, 146, 209-221.
43. Piccirillo, S.G. et al. (2009) Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene, 28, 1807-1811.
44. Gerlinger, M. et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med., 366, 883-892.
45. Calabrese, C. et al. (2007) A perivascular niche for brain tumor stem cells. Cancer Cell, 11, 69-82.
46. Toda, M. (2013) Glioma stem cells and immunotherapy for the treatment of malignant gliomas. ISRN Oncol., 2013, 673793.
47. Bourkoula, E. et al. (2014) Glioma-associated stem cells: a novel class of tumor-supporting cells able to predict prognosis of human low-grade gliomas. Stem Cells, 32, 1239-1253.
48. Bao, S. et al. (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res., 66, 7843-7848.
49. Nguyen, L.V. et al. (2012) Cancer stem cells: an evolving concept. Nat. Rev. Cancer, 12, 133-143.
50. Joo, K.M. et al. (2008) Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab. Invest., 88, 808-815.
51. Lottaz, C. et al. (2010) Transcriptional profiles of CD133+ and CD133-glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res., 70, 2030-2040.
52. Zeppernick, F. et al. (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res., 14, 123-129.
53. Christensen, K. et al. (2008) CD133 identifies perivascular niches in grade II-IV astrocytomas. J. Neurooncol., 90, 157-170.
54. Anido, J. et al. (2010) TGF-β receptor inhibitors target the CD44(high)/ Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell, 18, 655-668.
55. Xu, Y. et al. (2010) CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res., 70, 2455-2464.
56. Soroceanu, L. et al. (2013) Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res., 73, 1559-1569.
57. Al-Hajj, M. et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA., 100, 3983-3988.
58. Li, C. et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res., 67, 1030-1037.
59. Mao, P. et al. (2013) Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc. Natl. Acad. Sci. USA, 110, 8644-8649.
60. Liu, Q. et al. (2009) Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J. Neurooncol., 94, 1-19.
61. de Candia, P. et al. (2004) A role for Id proteins in mammary gland physiology and tumorigenesis. Adv. Cancer Res., 92, 81-94.
62. Maness, P.F. et al. (2007) Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat. Neurosci., 10, 19-26.
63. Arlt, M.J. et al. (2006) Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res., 66, 936-943.
64. Boo, Y.J. et al. (2007) L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann. Surg. Oncol., 14, 1703-1711.
65. Bao, S. et al. (2008) Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res., 68, 6043-6048.
66. Boccaccio, C. et al. (2013) The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. Cancer Res., 73, 3193-3199.
67. Joo, K.M. et al. (2012) MET signaling regulates glioblastoma stem cells. Cancer Res., 72, 3828-3838.
68. Li, Y. et al. (2011) c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc. Natl. Acad. Sci. USA, 108, 9951-9956.
69. De Bacco, F. et al. (2012) The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res., 72, 4537-4550.
70. Emlet, D.R. et al. (2014) Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. Cancer Res., 74, 1238-1249.
71. Moscatello, D.K. et al. (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res., 55, 5536-5539.
72. Choi, B.D. et al. (2009) EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol., 19, 713-723.
73. Guo, Y. et al. (2011) Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology, 59, 763-775.
74. Boyer, L.A. et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell, 122, 947-956.
75. Ben-Porath, I. et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet., 40, 499-507.
76. Balbous, A. et al. (2014) A mesenchymal glioma stem cell profile is related to clinical outcome. Oncogenesis, 3, e91.
77. Gangemi, R.M. et al. (2009) SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells, 27, 40-48.
78. Elsir, T. et al. (2014) A study of embryonic stem cell-related proteins in human astrocytomas: identification of Nanog as a predictor of survival. Int. J. Cancer, 134, 1123-1131.
79. Wu, J. et al. (2014) EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene, 33, 173-180.
80. Kim, J.E. et al. (2014) STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications. Cancers (Basel)., 6, 376-395.
81. Carro, M.S. et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature, 463, 318-325.
82. Fujiwara, Y. et al. (2011) Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3. Oncol. Rep., 26, 1533-1537.
83. Fuh, B. et al. (2009) LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br. J. Cancer, 100, 106-112.
84. Diehn, M. et al. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 458, 780-783.
85. Bao, S. et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756-760.
86. Liu, G. et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer, 5, 67.
87. Diaz, A. et al. (2011) Therapeutic approaches to target cancer stem cells. Cancers (Basel), 3, 3331-3352.
88. Ishikawa, F. et al. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol., 25, 1315-1321.
89. Harper, L.J. et al. (2010) Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer, 10, 166.
90. Harris, A.L. (2002) Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2, 38-47.
91. Griguer, C.E. et al. (2008) CD133 is a marker of bioenergetic stress in human glioma. PLoS One, 3, e3655.
92. Franovic, A. et al. (2007) Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc. Natl. Acad. Sci. USA, 104, 13092-13097.
93. Li, Z. et al. (2010) Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr. Top. Microbiol. Immunol., 345, 21-30.
94. Li, Z. et al. (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell, 15, 501-513.
95. Tanase, C.P. et al. (2013) Anti-cancer Therapies in High Grade Gliomas. Curr. Proteomics, 10, 246-260.
96. Reis, R.M. et al. (2000) Genetic profile of gliosarcomas. Am. J. Pathol., 156, 425-432.
97. Nagaishi, M. et al. (2012) Amplification of the STOML3, FREM2, and LHFP genes is associated with mesenchymal differentiation in gliosarcoma. Am. J. Pathol., 180, 1816-1823.
98. Nagaishi, M. et al. (2012) Transcriptional factors for epithelial-mesenchymal transition are associated with mesenchymal differentiation in gliosarcoma. Brain Pathol., 22, 670-676.
99. Kansara, M. et al. (2007) Molecular pathogenesis of osteosarcoma. DNA Cell Biol., 26, 1-18.
100. Pittenger, M.F. et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143-147.
101. Shin, D.M. et al. (2009) Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells. Leukemia, 23, 2042-2051.
102. Wojakowski, W. et al. (2009) Mobilization of bone marrow-derived Oct-4+ SSEA-4+ very small embryonic-like stem cells in patients with acute myocardial infarction. J. Am. Coll. Cardiol., 53, 1-9.
103. Levings, P.P. et al. (2009) Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res., 69, 5648-5655.
104. Behnan, J. et al. (2014) Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression. Stem Cells, 32, 1110-1123.
105. Wurmser, A.E. et al. (2004) Cell fusion-independent differentiation of neural stem cells to the endothelial lineage. Nature, 430, 350-356.
106. Luo, W. et al. (2013) Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. PLoS One, 8, e56324.
107. Stolzenburg, S. et al. (2012) Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res., 40, 6725-6740.
108. Beltran, A.S. et al. (2014) Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function. Oncogene, 33, 4767-4777.